Global Tumor Ablation

Tumor Ablation Comprehensive Study by Application (Liver Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Others), Treatment (Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation), Technology (Radiofrequency Ablation, Cryoablation, Microwave Ablation, Irreversible Electroporation, Other) Players and Region - Global Market Outlook to 2027

Tumor Ablation Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 11.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The tumor ablation is a minimally invasive technique that is commonly used in the treatment of tumors of the liver, kidney, bone and lung. It is an important option for people who have failed chemotherapy or radiotherapy or are not surgical candidates. It is also being considered a potential first-line treatment in many patients with small hepatocellular or benign tumors in the liver. According to AMA Research, the market for Tumor Ablation is expected to register a CAGR of 11.9% during the forecast period to 2027. This growth is primarily driven by Increase in the Prevalence of the Cancer Worldwide .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitUSD (Million)
Key Companies in StudyBoston Scientific Corporation (United States), Angiodynamics, Inc. (United States), Galil Medical, Inc. (United States), EDAP TMS S.A. (France), Healthtronics, Inc. (United States), Medtronic, Plc (United States), Mesonix, Inc. (United States), Sonacare Medical, LLC (United States), Mermaid Medical, Inc. (Denmark) and Neuwave Medical, Inc. (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Technology sector in the Asia Pacific region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Boston Scientific Corporation (United States), Angiodynamics, Inc. (United States), Galil Medical, Inc. (United States), EDAP TMS S.A. (France), Healthtronics, Inc. (United States), Medtronic, Plc (United States), Mesonix, Inc. (United States), Sonacare Medical, LLC (United States), Mermaid Medical, Inc. (Denmark) and Neuwave Medical, Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In 2022, Quantum Surgical is 510(k)-approved by the U.S. Food and Drug Administration (FDA) for Epione, which enables clinicians to perform safe and efficient percutaneous tumor resection., In 2021, Bioventus Inc. has acquired Misonix, Inc., a supplier of minimally invasive therapeutic ultrasound technology and regenerative medicine that improves clinical outcomes. Mixonix offers SonaSrar tumor resection solutions to help speed up surgery and help with precise soft tissue removal. and In 2021, Boston Scientific Corporation has acquired the remaining interest in Farapulse, Inc. This acquisition is associated with atrial fibrillation (AF) and other cardiac arrhythmias.
In 2022, IceCure Medical Ltd. has submitted a regulatory filing to the Brazilian Health Regulatory Agency (“ANVISA”) for approval of ProSense, an advanced liquid nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing. It focuses on breast cancer, kidney cancer, bone and lung cancer., In 2021, Medtronic plc has received Breakthrough Device Designation status from the US Food and Drug Administration (FDA) for the Emprint Ablation Catheter Kit. The FDA Innovative Devices Program aims to provide patients access to breakthrough technologies that have the potential to improve the treatment or diagnosis of life-threatening or irreversibly debilitating diseases and disorders. and In 2020, SonaCare Medical has received regulatory approval from the National Medical Products Administration (NMPA), formerly known as the Chinese FDA, for the Sonablate HIFU device used to treat prostate cancer and benign prostatic hyperplasia (BPH).

Market Drivers
  • Increase in the Prevalence of the Cancer Worldwide
  • Technological Advancements in the Tumor Ablation Technique
  • Growing Awareness about Cancer Treatment among the People
  • Increase in Healthcare Expenditure

Market Trend
  • Demand for Innovative Techniques for Cancer Treatment

Restraints
  • Unfavorable regulatory policies adopted by various governments are restraining market growth.

Opportunities
Development of Healthcare Infrastructure in Emerging Economies, Development of New Diagnostic Centre and Hospitals and Growing Geriatric Population Worldwide
Challenges
Exorbitant Cost of Tumor Ablation Technique

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Tumor Ablation Study Sheds Light on
— The Tumor Ablation Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Tumor Ablation industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Tumor Ablation industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Liver Cancer
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others
By Treatment
  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Technology
  • Radiofrequency Ablation
  • Cryoablation
  • Microwave Ablation
  • Irreversible Electroporation
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of the Cancer Worldwide
      • 3.2.2. Technological Advancements in the Tumor Ablation Technique
      • 3.2.3. Growing Awareness about Cancer Treatment among the People
      • 3.2.4. Increase in Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Exorbitant Cost of Tumor Ablation Technique
    • 3.4. Market Trends
      • 3.4.1. Demand for Innovative Techniques for Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tumor Ablation, by Application, Treatment, Technology and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Tumor Ablation (Value)
      • 5.2.1. Global Tumor Ablation by: Application (Value)
        • 5.2.1.1. Liver Cancer
        • 5.2.1.2. Lung Cancer
        • 5.2.1.3. Breast Cancer
        • 5.2.1.4. Prostate Cancer
        • 5.2.1.5. Others
      • 5.2.2. Global Tumor Ablation by: Treatment (Value)
        • 5.2.2.1. Surgical Ablation
        • 5.2.2.2. Laparoscopic Ablation
        • 5.2.2.3. Percutaneous Ablation
      • 5.2.3. Global Tumor Ablation by: Technology (Value)
        • 5.2.3.1. Radiofrequency Ablation
        • 5.2.3.2. Cryoablation
        • 5.2.3.3. Microwave Ablation
        • 5.2.3.4. Irreversible Electroporation
        • 5.2.3.5. Other
      • 5.2.4. Global Tumor Ablation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Tumor Ablation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Angiodynamics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Galil Medical, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. EDAP TMS S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Healthtronics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medtronic, Plc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mesonix, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sonacare Medical, LLC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mermaid Medical, Inc. (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Neuwave Medical, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tumor Ablation Sale, by Application, Treatment, Technology and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Tumor Ablation (Value)
      • 7.2.1. Global Tumor Ablation by: Application (Value)
        • 7.2.1.1. Liver Cancer
        • 7.2.1.2. Lung Cancer
        • 7.2.1.3. Breast Cancer
        • 7.2.1.4. Prostate Cancer
        • 7.2.1.5. Others
      • 7.2.2. Global Tumor Ablation by: Treatment (Value)
        • 7.2.2.1. Surgical Ablation
        • 7.2.2.2. Laparoscopic Ablation
        • 7.2.2.3. Percutaneous Ablation
      • 7.2.3. Global Tumor Ablation by: Technology (Value)
        • 7.2.3.1. Radiofrequency Ablation
        • 7.2.3.2. Cryoablation
        • 7.2.3.3. Microwave Ablation
        • 7.2.3.4. Irreversible Electroporation
        • 7.2.3.5. Other
      • 7.2.4. Global Tumor Ablation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tumor Ablation: by Application(USD Million)
  • Table 2. Tumor Ablation Liver Cancer , by Region USD Million (2016-2021)
  • Table 3. Tumor Ablation Lung Cancer , by Region USD Million (2016-2021)
  • Table 4. Tumor Ablation Breast Cancer , by Region USD Million (2016-2021)
  • Table 5. Tumor Ablation Prostate Cancer , by Region USD Million (2016-2021)
  • Table 6. Tumor Ablation Others , by Region USD Million (2016-2021)
  • Table 7. Tumor Ablation: by Treatment(USD Million)
  • Table 8. Tumor Ablation Surgical Ablation , by Region USD Million (2016-2021)
  • Table 9. Tumor Ablation Laparoscopic Ablation , by Region USD Million (2016-2021)
  • Table 10. Tumor Ablation Percutaneous Ablation , by Region USD Million (2016-2021)
  • Table 11. Tumor Ablation: by Technology(USD Million)
  • Table 12. Tumor Ablation Radiofrequency Ablation , by Region USD Million (2016-2021)
  • Table 13. Tumor Ablation Cryoablation , by Region USD Million (2016-2021)
  • Table 14. Tumor Ablation Microwave Ablation , by Region USD Million (2016-2021)
  • Table 15. Tumor Ablation Irreversible Electroporation , by Region USD Million (2016-2021)
  • Table 16. Tumor Ablation Other , by Region USD Million (2016-2021)
  • Table 17. South America Tumor Ablation, by Country USD Million (2016-2021)
  • Table 18. South America Tumor Ablation, by Application USD Million (2016-2021)
  • Table 19. South America Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 20. South America Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 21. Brazil Tumor Ablation, by Application USD Million (2016-2021)
  • Table 22. Brazil Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 23. Brazil Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 24. Argentina Tumor Ablation, by Application USD Million (2016-2021)
  • Table 25. Argentina Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 26. Argentina Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 27. Rest of South America Tumor Ablation, by Application USD Million (2016-2021)
  • Table 28. Rest of South America Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 29. Rest of South America Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 30. Asia Pacific Tumor Ablation, by Country USD Million (2016-2021)
  • Table 31. Asia Pacific Tumor Ablation, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 33. Asia Pacific Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 34. China Tumor Ablation, by Application USD Million (2016-2021)
  • Table 35. China Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 36. China Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 37. Japan Tumor Ablation, by Application USD Million (2016-2021)
  • Table 38. Japan Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 39. Japan Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 40. India Tumor Ablation, by Application USD Million (2016-2021)
  • Table 41. India Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 42. India Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 43. South Korea Tumor Ablation, by Application USD Million (2016-2021)
  • Table 44. South Korea Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 45. South Korea Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 46. Taiwan Tumor Ablation, by Application USD Million (2016-2021)
  • Table 47. Taiwan Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 48. Taiwan Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 49. Australia Tumor Ablation, by Application USD Million (2016-2021)
  • Table 50. Australia Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 51. Australia Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Tumor Ablation, by Application USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 55. Europe Tumor Ablation, by Country USD Million (2016-2021)
  • Table 56. Europe Tumor Ablation, by Application USD Million (2016-2021)
  • Table 57. Europe Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 58. Europe Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 59. Germany Tumor Ablation, by Application USD Million (2016-2021)
  • Table 60. Germany Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 61. Germany Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 62. France Tumor Ablation, by Application USD Million (2016-2021)
  • Table 63. France Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 64. France Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 65. Italy Tumor Ablation, by Application USD Million (2016-2021)
  • Table 66. Italy Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 67. Italy Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 68. United Kingdom Tumor Ablation, by Application USD Million (2016-2021)
  • Table 69. United Kingdom Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 70. United Kingdom Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 71. Netherlands Tumor Ablation, by Application USD Million (2016-2021)
  • Table 72. Netherlands Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 73. Netherlands Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 74. Rest of Europe Tumor Ablation, by Application USD Million (2016-2021)
  • Table 75. Rest of Europe Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 76. Rest of Europe Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 77. MEA Tumor Ablation, by Country USD Million (2016-2021)
  • Table 78. MEA Tumor Ablation, by Application USD Million (2016-2021)
  • Table 79. MEA Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 80. MEA Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 81. Middle East Tumor Ablation, by Application USD Million (2016-2021)
  • Table 82. Middle East Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 83. Middle East Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 84. Africa Tumor Ablation, by Application USD Million (2016-2021)
  • Table 85. Africa Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 86. Africa Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 87. North America Tumor Ablation, by Country USD Million (2016-2021)
  • Table 88. North America Tumor Ablation, by Application USD Million (2016-2021)
  • Table 89. North America Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 90. North America Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 91. United States Tumor Ablation, by Application USD Million (2016-2021)
  • Table 92. United States Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 93. United States Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 94. Canada Tumor Ablation, by Application USD Million (2016-2021)
  • Table 95. Canada Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 96. Canada Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 97. Mexico Tumor Ablation, by Application USD Million (2016-2021)
  • Table 98. Mexico Tumor Ablation, by Treatment USD Million (2016-2021)
  • Table 99. Mexico Tumor Ablation, by Technology USD Million (2016-2021)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Tumor Ablation: by Application(USD Million)
  • Table 111. Tumor Ablation Liver Cancer , by Region USD Million (2022-2027)
  • Table 112. Tumor Ablation Lung Cancer , by Region USD Million (2022-2027)
  • Table 113. Tumor Ablation Breast Cancer , by Region USD Million (2022-2027)
  • Table 114. Tumor Ablation Prostate Cancer , by Region USD Million (2022-2027)
  • Table 115. Tumor Ablation Others , by Region USD Million (2022-2027)
  • Table 116. Tumor Ablation: by Treatment(USD Million)
  • Table 117. Tumor Ablation Surgical Ablation , by Region USD Million (2022-2027)
  • Table 118. Tumor Ablation Laparoscopic Ablation , by Region USD Million (2022-2027)
  • Table 119. Tumor Ablation Percutaneous Ablation , by Region USD Million (2022-2027)
  • Table 120. Tumor Ablation: by Technology(USD Million)
  • Table 121. Tumor Ablation Radiofrequency Ablation , by Region USD Million (2022-2027)
  • Table 122. Tumor Ablation Cryoablation , by Region USD Million (2022-2027)
  • Table 123. Tumor Ablation Microwave Ablation , by Region USD Million (2022-2027)
  • Table 124. Tumor Ablation Irreversible Electroporation , by Region USD Million (2022-2027)
  • Table 125. Tumor Ablation Other , by Region USD Million (2022-2027)
  • Table 126. South America Tumor Ablation, by Country USD Million (2022-2027)
  • Table 127. South America Tumor Ablation, by Application USD Million (2022-2027)
  • Table 128. South America Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 129. South America Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 130. Brazil Tumor Ablation, by Application USD Million (2022-2027)
  • Table 131. Brazil Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 132. Brazil Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 133. Argentina Tumor Ablation, by Application USD Million (2022-2027)
  • Table 134. Argentina Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 135. Argentina Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 136. Rest of South America Tumor Ablation, by Application USD Million (2022-2027)
  • Table 137. Rest of South America Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 138. Rest of South America Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 139. Asia Pacific Tumor Ablation, by Country USD Million (2022-2027)
  • Table 140. Asia Pacific Tumor Ablation, by Application USD Million (2022-2027)
  • Table 141. Asia Pacific Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 142. Asia Pacific Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 143. China Tumor Ablation, by Application USD Million (2022-2027)
  • Table 144. China Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 145. China Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 146. Japan Tumor Ablation, by Application USD Million (2022-2027)
  • Table 147. Japan Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 148. Japan Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 149. India Tumor Ablation, by Application USD Million (2022-2027)
  • Table 150. India Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 151. India Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 152. South Korea Tumor Ablation, by Application USD Million (2022-2027)
  • Table 153. South Korea Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 154. South Korea Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 155. Taiwan Tumor Ablation, by Application USD Million (2022-2027)
  • Table 156. Taiwan Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 157. Taiwan Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 158. Australia Tumor Ablation, by Application USD Million (2022-2027)
  • Table 159. Australia Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 160. Australia Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 161. Rest of Asia-Pacific Tumor Ablation, by Application USD Million (2022-2027)
  • Table 162. Rest of Asia-Pacific Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 163. Rest of Asia-Pacific Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 164. Europe Tumor Ablation, by Country USD Million (2022-2027)
  • Table 165. Europe Tumor Ablation, by Application USD Million (2022-2027)
  • Table 166. Europe Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 167. Europe Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 168. Germany Tumor Ablation, by Application USD Million (2022-2027)
  • Table 169. Germany Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 170. Germany Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 171. France Tumor Ablation, by Application USD Million (2022-2027)
  • Table 172. France Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 173. France Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 174. Italy Tumor Ablation, by Application USD Million (2022-2027)
  • Table 175. Italy Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 176. Italy Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 177. United Kingdom Tumor Ablation, by Application USD Million (2022-2027)
  • Table 178. United Kingdom Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 179. United Kingdom Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 180. Netherlands Tumor Ablation, by Application USD Million (2022-2027)
  • Table 181. Netherlands Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 182. Netherlands Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 183. Rest of Europe Tumor Ablation, by Application USD Million (2022-2027)
  • Table 184. Rest of Europe Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 185. Rest of Europe Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 186. MEA Tumor Ablation, by Country USD Million (2022-2027)
  • Table 187. MEA Tumor Ablation, by Application USD Million (2022-2027)
  • Table 188. MEA Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 189. MEA Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 190. Middle East Tumor Ablation, by Application USD Million (2022-2027)
  • Table 191. Middle East Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 192. Middle East Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 193. Africa Tumor Ablation, by Application USD Million (2022-2027)
  • Table 194. Africa Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 195. Africa Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 196. North America Tumor Ablation, by Country USD Million (2022-2027)
  • Table 197. North America Tumor Ablation, by Application USD Million (2022-2027)
  • Table 198. North America Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 199. North America Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 200. United States Tumor Ablation, by Application USD Million (2022-2027)
  • Table 201. United States Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 202. United States Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 203. Canada Tumor Ablation, by Application USD Million (2022-2027)
  • Table 204. Canada Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 205. Canada Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 206. Mexico Tumor Ablation, by Application USD Million (2022-2027)
  • Table 207. Mexico Tumor Ablation, by Treatment USD Million (2022-2027)
  • Table 208. Mexico Tumor Ablation, by Technology USD Million (2022-2027)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tumor Ablation: by Application USD Million (2016-2021)
  • Figure 5. Global Tumor Ablation: by Treatment USD Million (2016-2021)
  • Figure 6. Global Tumor Ablation: by Technology USD Million (2016-2021)
  • Figure 7. South America Tumor Ablation Share (%), by Country
  • Figure 8. Asia Pacific Tumor Ablation Share (%), by Country
  • Figure 9. Europe Tumor Ablation Share (%), by Country
  • Figure 10. MEA Tumor Ablation Share (%), by Country
  • Figure 11. North America Tumor Ablation Share (%), by Country
  • Figure 12. Global Tumor Ablation share by Players 2021 (%)
  • Figure 13. Global Tumor Ablation share by Players (Top 3) 2021(%)
  • Figure 14. Global Tumor Ablation share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 17. Boston Scientific Corporation (United States) Revenue: by Geography 2021
  • Figure 18. Angiodynamics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Angiodynamics, Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Galil Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Galil Medical, Inc. (United States) Revenue: by Geography 2021
  • Figure 22. EDAP TMS S.A. (France) Revenue, Net Income and Gross profit
  • Figure 23. EDAP TMS S.A. (France) Revenue: by Geography 2021
  • Figure 24. Healthtronics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Healthtronics, Inc. (United States) Revenue: by Geography 2021
  • Figure 26. Medtronic, Plc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Medtronic, Plc (United States) Revenue: by Geography 2021
  • Figure 28. Mesonix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mesonix, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Sonacare Medical, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sonacare Medical, LLC (United States) Revenue: by Geography 2021
  • Figure 32. Mermaid Medical, Inc. (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Mermaid Medical, Inc. (Denmark) Revenue: by Geography 2021
  • Figure 34. Neuwave Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Neuwave Medical, Inc. (United States) Revenue: by Geography 2021
  • Figure 36. Global Tumor Ablation: by Application USD Million (2022-2027)
  • Figure 37. Global Tumor Ablation: by Treatment USD Million (2022-2027)
  • Figure 38. Global Tumor Ablation: by Technology USD Million (2022-2027)
  • Figure 39. South America Tumor Ablation Share (%), by Country
  • Figure 40. Asia Pacific Tumor Ablation Share (%), by Country
  • Figure 41. Europe Tumor Ablation Share (%), by Country
  • Figure 42. MEA Tumor Ablation Share (%), by Country
  • Figure 43. North America Tumor Ablation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boston Scientific Corporation (United States)
  • Angiodynamics, Inc. (United States)
  • Galil Medical, Inc. (United States)
  • EDAP TMS S.A. (France)
  • Healthtronics, Inc. (United States)
  • Medtronic, Plc (United States)
  • Mesonix, Inc. (United States)
  • Sonacare Medical, LLC (United States)
  • Mermaid Medical, Inc. (Denmark)
  • Neuwave Medical, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 170 Pages 73 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tumor Ablation Quantitative research analysis
Global Tumor Ablation Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Tumor Ablation Market are Boston Scientific Corporation (United States), Angiodynamics, Inc. (United States), Galil Medical, Inc. (United States), EDAP TMS S.A. (France), Healthtronics, Inc. (United States), Medtronic, Plc (United States), Mesonix, Inc. (United States), Sonacare Medical, LLC (United States), Mermaid Medical, Inc. (Denmark) and Neuwave Medical, Inc. (United States) etc.
Liver Cancer segment in Global market to hold robust market share owing to "Increase in the Prevalence of the Cancer Worldwide ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Tumor Ablation market throughout the forecasted period.

Know More About Global Tumor Ablation Report?

Have a Query? Click Here

Other Related Reports

Breakthrough Therapy Comprehensive Study by Application (Oncology, Infectious Diseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, Neurological Disorders, Others), End-users (Hospitals, ...
$ 3450
Medical Document Management Systems Comprehensive Study by Type (Solution, Service), Application (Patient Medical Records Management, Image Management, Admission and Registration Documents Management...
$ 3750
Medical Holography Comprehensive Study by Type (Holographic Display, Microscope, Print, Software), Application (Medical Imaging, Medical Education, Biomedical Research), Holographic Display (Laser, T...
$ 3750
Medical Simulation Comprehensive Study by Type (Intelligent System, Fully Automatic, Semi-Automatic, Manual Control, Other), Application (Medical Colleges, Hospitals, Medical Training Institutions, O...
$ 3650
Flat Panel Detector Comprehensive Study by Type (Portable Flat Panel Detector, Wireless Flat Panel Detector), Application (Hospital & Clinic, Scientific Research, Other), Size Type (Small-Area Flat-P...
$ 3450
Food Allergen Testing Comprehensive Study by Application (Meat and Poultry, Dairy, Fruits and Vegetables, Processed Foods, Crops, Others), Technology (HPLC-based, LC-MS/MS-based, Immunoassay-based, O...
$ 3450